GlassScriptPhysician profile
Nadra Monica Saad
NPI 1790701886
$2,429.57
in general payments reported to CMS, 2019-2025
31 companies · $100 in 2025
The $100 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $411 · 2021: $593 · 2022: $227 · 2023: $400 · 2024: $291 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.75 | 2019-2024 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $222.32 | 2020-2022 | |
| Corium, LLC | $176.10 | 2021-2024 | Azstarys |
| Pfizer INC. | $165.02 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.05 | 2020-2023 | Takhzyro |
| Cranial Technologies, INC | $142.36 | 2019-2025 | Doc Band |
| Regeneron Healthcare Solutions, INC. | $125.05 | 2022-2023 | Dupixent |
| Genzyme Corporation | $118.98 | 2024 | |
| Sanofi Pasteur INC. | $115.91 | 2019-2024 | |
| Glaxosmithkline, LLC. | $105.59 | 2019-2024 | Arexvy, Shingrix |
| Kaleo, INC. | $96.12 | 2021-2023 | Auvi-Q |
| Lilly USA, LLC | $84.10 | 2021-2024 | Trulicity, Basaglar, Mounjaro |
| Avanir Pharmaceuticals, INC. | $80.56 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.56 | 2019-2020 | |
| Neos Therapeutics, LP | $68.44 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $57.05 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $54.84 | 2019-2023 | Gardasil 9, Vaxneuvance, Rotateq |
| Teva Pharmaceuticals USA, INC. | $51.23 | 2021 | |
| Genentech USA, INC. | $38.70 | 2019-2021 | |
| Amgen INC. | $31.90 | 2025 | Actimmune |
| Supernus Pharmaceuticals, INC. | $28.64 | 2021 | |
| Incyte Corporation | $28.61 | 2023 | Opzelura |
| Otsuka America Pharmaceutical, INC. | $22.67 | 2021 | |
| Horizon Therapeutics Plc | $20.49 | 2019 | |
| Bausch Health US, LLC | $19.40 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $18.74 | 2025 | Neffy |
| Medimetriks Pharmaceuticals, INC. | $17.87 | 2023 | Neo-Synalar |
| Shire North American Group INC | $17.83 | 2019 | |
| Alk-Abello, INC | $16.96 | 2020 | |
| Phadia US INC. | $13.87 | 2025 | Immunocap |
| Arbor Pharmaceuticals, INC. | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadra Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.